Articles Vol. 65 No. CĐ 3 - Bệnh viện Phổi Trung ương 15/05/2024

36. INITIAL STUDY TO DISTINGUISH LUNG CANCER AND BENIGN LUNG DISEASE USING SHOX2 GENE METHYL MARKER FROM LUNG BIOPSY AND LIQUID BIOPSY SAMPLE

Phuong Ngoc Anh1,2,3,4, Dao Thuy Trang4,5, Nguyen Van Ba6,7, Ho Huu Tho4,5
1 National Lung Hospital
2 Military Medical and Pharmaceutical Research Institute
3 Bệnh viện Phổi Trung ương
4 Viện Nghiên cứu Y dược học Quân sự, Học viện Quân y
5 Military Medical and Pharmaceutical Research Institute, Vietnam Military Medical Academy
6 Department of Military Science, Vietnam Military Medical Academy
7 Phòng Khoa học Quân sự, Học viện Quân y
Corresponding author: Hohuutho@vmmu.edu.vn
DOI: 10.52163/yhc.v65iCD3.1133
15 Views
6 Downloads
Keywords
DNA methylation; SHOX2; Lung cancer; Liquid biopsy; Realtime PCR.
Abstract

This study explores the potential of SHOX2 DNA methylation as a biomarker to distinguish lung cancer from benign lung diseases. We conducted analyzes on both lung tissue samples and plasma samples from lung cancer patients and the control group. Using Realtime PCR technology with extendable lock probes and TaqMan probes, we aimed to increase the sensitivity and specificity of the method, which is important in handling samples with low tumor DNA concentrations. Results showed significant detection of SHOX2 methylation in lung cancer patients compared with controls, both in tissue and plasma samples, demonstrating the potential of this marker in early and non-invasive diagnosis of cancer. lung cancer. Statistical analysis confirmed significant differences between the two groups, reinforcing the role of SHOX2 as an effective biomarker. Although the results are promising, further research is needed to confirm the broad applicability of the method. Improving the chances of diagnosing and treating lung cancer, the study highlights the importance of developing new biomarkers and precise analysis technology.

References
[1]
Sung H., Ferlay J., Siegel R.L. et al., Global Google Scholar
[2]
Cancer Statistics 2020: GLOBOCAN Estimates Google Scholar
[3]
of Incidence and Mortality Worldwide for 36 Google Scholar
[4]
Cancers in 185 Countries. CA Cancer J Clin, Google Scholar
[5]
(3), 2021, 209–249. Google Scholar
[6]
Wang S., Dong L., Wang X. et al., Classification Google Scholar
[7]
of Pathological Types of Lung Cancer from Google Scholar
[8]
CT Images by Deep Residual Neural Networks Google Scholar
[9]
with Transfer Learning Strategy. Open Med, 15, Google Scholar
[10]
, 190–197. Google Scholar
[11]
Kalinke L., Thakrar R., Janes S.M., The promises Google Scholar
[12]
and challenges of early non‐small cell lung Google Scholar
[13]
cancer detection: Patient perceptions, low‐dose Google Scholar
[14]
CT screening, bronchoscopy and biomarkers. Google Scholar
[15]
Mol Oncol, 15(10), 2021, 2544–2564. Google Scholar
[16]
Reduced Lung-Cancer Mortality with Low-Dose Google Scholar
[17]
Computed Tomographic Screening. N Engl J Google Scholar
[18]
Med, 365(5), 2011, 395–409. Google Scholar
[19]
Kalari S., Jung M., Kernstine K.H. et al., The Google Scholar
[20]
DNA methylation landscape of small cell lung Google Scholar
[21]
cancer suggests a differentiation defect of neuroendocrine Google Scholar
[22]
cells. Oncogene, 32(30), 2013, 3559–3568. Google Scholar
[23]
Rauch T., Wang Z., Zhang X. et al., Homeobox Google Scholar
[24]
gene methylation in lung cancer studied by genome- Google Scholar
[25]
wide analysis with a microarray-based Google Scholar
[26]
methylated CpG island recovery assay. Proc Natl Google Scholar
[27]
Acad Sci U S A, 104(13), 2007, 5527–5532. Google Scholar
[28]
Rauch T.A., Zhong X., Wu X. et al., High-resolution Google Scholar
[29]
mapping of DNA hypermethylation and Google Scholar
[30]
hypomethylation in lung cancer. Proc Natl Acad Google Scholar
[31]
Sci U S A, 105(1), 2008, 252–257. Google Scholar
[32]
Rauch T.A., Wang Z., Wu X. et al., DNA methylation Google Scholar
[33]
biomarkers for lung cancer. Tumour Biol Google Scholar
[34]
J Int Soc Oncodevelopmental Biol Med, 33(2), Google Scholar
[35]
, 287–296. Google Scholar
[36]
Kneip C., Schmidt B., Seegebarth A. et al., Google Scholar
[37]
SHOX2 DNA methylation is a biomarker for Google Scholar
[38]
the diagnosis of lung cancer in plasma. J Thorac Google Scholar
[39]
Oncol Off Publ Int Assoc Study Lung Cancer, Google Scholar
[40]
(10), 2011, 1632–1638. Google Scholar
[41]
Ilse P., Biesterfeld S., Pomjanski N. et al., Analysis Google Scholar
[42]
of SHOX2 methylation as an aid to cytology Google Scholar
[43]
in lung cancer diagnosis. Cancer Genomics Proteomics, Google Scholar
[44]
(5), 2014, 251–258. Google Scholar
[45]
Schmidt B., Liebenberg V., Dietrich D. et al., Google Scholar
[46]
SHOX2 DNA methylation is a biomarker Google Scholar
[47]
Ho T.H., Dang K.X., Lintula S. và cộng sự. Google Scholar
[48]
(2015). Extendable blocking probe in reverse Google Scholar
[49]
transcription for analysis of RNA variants with Google Scholar
[50]
superior selectivity. Nucleic Acids Res, 43(1), Google Scholar
[51]
, e4. Google Scholar
[52]
Song P, Wu LR, Yan YH et al., Limitations and Google Scholar
[53]
opportunities of technologies for the analysis of Google Scholar
[54]
cell-free DNA in cancer diagnostics. Nat Biomed Google Scholar
[55]
Eng. 2022 Mar;6(3):232-245. doi: 10.1038/ Google Scholar
[56]
s41551-021-00837-3. Epub 2022 Jan 31. PMID: Google Scholar
[57]
; PMCID: PMC9336539. Google Scholar
[58]
Vo T.T.L., Nguyen T.N., Nguyen T.T. et al., Google Scholar
[59]
SHOX2 methylation in Vietnamese patients Google Scholar
[60]
with lung cancer. Mol Biol Rep, 49(5), 2022, Google Scholar
[61]
–3421. Google Scholar